These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23494865)

  • 21. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A practical, evidence-based guide to the use of adalimumab in Crohn's disease.
    Rubin DT; Panaccione R; Chao J; Robinson AM
    Curr Med Res Opin; 2011 Sep; 27(9):1803-13. PubMed ID: 21809894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Adalimumab as induction therapy for Crohn's disease - one center study].
    Gonciarz M; Mularczyk A; Szkudłapski D; Piątek I; Kopała M
    Pol Merkur Lekarski; 2016 Nov; 41(245):216-220. PubMed ID: 27883347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity.
    Eder P; Katulska K; Krela-Kaźmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K; Łykowska-Szuber L
    Abdom Imaging; 2015 Oct; 40(7):2210-8. PubMed ID: 26048698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease.
    Khanna R; Zou G; Stitt L; Feagan BG; Sandborn WJ; Rutgeerts P; McDonald JWD; Dubcenco E; Fogel R; Panaccione R; Jairath V; Nelson S; Shackelton LM; Huang B; Zhou Q; Robinson AM; Levesque BG; D'Haens G
    Am J Gastroenterol; 2017 Oct; 112(10):1584-1592. PubMed ID: 28071654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease.
    Ma C; Walters B; Fedorak RN
    World J Gastroenterol; 2013 Jun; 19(21):3347-51. PubMed ID: 23745038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
    Bouhnik Y; Carbonnel F; Laharie D; Stefanescu C; Hébuterne X; Abitbol V; Nachury M; Brixi H; Bourreille A; Picon L; Bourrier A; Allez M; Peyrin-Biroulet L; Moreau J; Savoye G; Fumery M; Nancey S; Roblin X; Altwegg R; Bouguen G; Bommelaer G; Danese S; Louis E; Zappa M; Mary JY;
    Gut; 2018 Jan; 67(1):53-60. PubMed ID: 28119352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of oral Crohn's disease by anti-TNF-alpha dose escalation - a case report.
    Bokemeyer A; Tentrop N; Barth PJ; Lenze F; Hengst K; Kleinheinz J; Bettenworth D
    BMC Gastroenterol; 2018 Jun; 18(1):88. PubMed ID: 29914414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lower adalimumab trough levels are associated with higher bowel wall thickness in Crohn's disease.
    Ungar B; Ben-Shatach Z; Selinger L; Malik A; Albshesh A; Ben-Horin S; Eliakim R; Kopylov U; Carter D
    United European Gastroenterol J; 2020 Mar; 8(2):167-174. PubMed ID: 32213067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease.
    Rahman FZ; Takhar GK; Roy O; Shepherd A; Bloom SL; McCartney SA
    World J Gastrointest Pharmacol Ther; 2010 Oct; 1(5):119-22. PubMed ID: 21577306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report.
    Barreiro-de Acosta M; Ouburg S; Morré SA; Crusius JB; Lorenzo A; Potel J; Salvador-Peña A; Domínguez-Muñoz JE
    Rev Esp Enferm Dig; 2010 Oct; 102(10):591-5. PubMed ID: 21039068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab in pediatric Crohn's disease.
    Patel AS; Suarez LD; Rosh JR
    Immunotherapy; 2016 Feb; 8(2):127-33. PubMed ID: 26787222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
    Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
    J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn's Disease: Final Results.
    Zullow S; Flasar MH; Greenberg D; Tracy JK; Rustgi A; Cross RK
    Gastroenterol Hepatol (N Y); 2014 Aug; 10(8):503-509. PubMed ID: 28845141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.